128 related articles for article (PubMed ID: 10858966)
1. [Chemical inhibitors of cyclic-dependent kinases: preclinical and clinical study].
Damiens E; Meijer L
Pathol Biol (Paris); 2000 Apr; 48(3):340-51. PubMed ID: 10858966
[TBL] [Abstract][Full Text] [Related]
2. Discovery and initial characterization of the paullones, a novel class of small-molecule inhibitors of cyclin-dependent kinases.
Zaharevitz DW; Gussio R; Leost M; Senderowicz AM; Lahusen T; Kunick C; Meijer L; Sausville EA
Cancer Res; 1999 Jun; 59(11):2566-9. PubMed ID: 10363974
[TBL] [Abstract][Full Text] [Related]
3. CDK inhibitors in cancer therapy: what is next?
Malumbres M; Pevarello P; Barbacid M; Bischoff JR
Trends Pharmacol Sci; 2008 Jan; 29(1):16-21. PubMed ID: 18054800
[TBL] [Abstract][Full Text] [Related]
4. Small molecule modulators of cyclin-dependent kinases for cancer therapy.
Senderowicz AM
Oncogene; 2000 Dec; 19(56):6600-6. PubMed ID: 11426645
[TBL] [Abstract][Full Text] [Related]
5. [Development of antituberculous drugs: current status and future prospects].
Tomioka H; Namba K
Kekkaku; 2006 Dec; 81(12):753-74. PubMed ID: 17240921
[TBL] [Abstract][Full Text] [Related]
6. Clinical trials referral resource. Clinical trials of flavopiridol.
Wright J; Blatner GL; Cheson BD
Oncology (Williston Park); 1998 Jul; 12(7):1018, 1023-4. PubMed ID: 9684276
[No Abstract] [Full Text] [Related]
7. Recent advances and new directions in the discovery and development of cyclin-dependent kinase inhibitors.
Fischer PM
Curr Opin Drug Discov Devel; 2001 Sep; 4(5):623-34. PubMed ID: 12825457
[TBL] [Abstract][Full Text] [Related]
8. Flavopiridol increases therapeutic ratio of radiotherapy by preferentially enhancing tumor radioresponse.
Mason KA; Hunter NR; Raju U; Ariga H; Husain A; Valdecanas D; Neal R; Ang KK; Milas L
Int J Radiat Oncol Biol Phys; 2004 Jul; 59(4):1181-9. PubMed ID: 15234054
[TBL] [Abstract][Full Text] [Related]
9. Flavopiridol, an inhibitor of cyclin-dependent kinases, induces growth inhibition and apoptosis in bladder cancer cells in vitro and in vivo.
Wirger A; Perabo FG; Burgemeister S; Haase L; Schmidt DH; Doehn C; Mueller SC; Jocham D
Anticancer Res; 2005; 25(6B):4341-7. PubMed ID: 16309238
[TBL] [Abstract][Full Text] [Related]
10. Cyclin-dependent kinase inhibitors.
Fischer PM; Endicott J; Meijer L
Prog Cell Cycle Res; 2003; 5():235-48. PubMed ID: 14593718
[TBL] [Abstract][Full Text] [Related]
11. [Therapeutic effect of flavopiridol, a small molecular cyclin-dependent kinase inhibitor, in human ovarian carcinoma].
Song Y; Shen K; Tang PP
Zhonghua Fu Chan Ke Za Zhi; 2007 Nov; 42(11):761-4. PubMed ID: 18307904
[TBL] [Abstract][Full Text] [Related]
12. Cyclin-dependent kinase modulators studied at the NCI: pre-clinical and clinical studies.
Sausville EA
Curr Med Chem Anticancer Agents; 2003 Jan; 3(1):47-56. PubMed ID: 12678914
[TBL] [Abstract][Full Text] [Related]
13. Improvement of esophageal adenocarcinoma cell and xenograft responses to radiation by targeting cyclin-dependent kinases.
Raju U; Ariga H; Koto M; Lu X; Pickett J; Valdecanas D; Mason KA; Milas L
Radiother Oncol; 2006 Aug; 80(2):185-91. PubMed ID: 16905211
[TBL] [Abstract][Full Text] [Related]
14. Cyclin-dependent kinase modulators: a novel class of cell cycle regulators for cancer therapy.
Senderowicz AM
Cancer Chemother Biol Response Modif; 2001; 19():165-88. PubMed ID: 11686013
[TBL] [Abstract][Full Text] [Related]
15. Preclinical and clinical development of cyclin-dependent kinase modulators.
Senderowicz AM; Sausville EA
J Natl Cancer Inst; 2000 Mar; 92(5):376-87. PubMed ID: 10699068
[TBL] [Abstract][Full Text] [Related]
16. Structural basis for inhibition of cyclin-dependent kinase 9 by flavopiridol.
de Azevedo WF; Canduri F; da Silveira NJ
Biochem Biophys Res Commun; 2002 Apr; 293(1):566-71. PubMed ID: 12054639
[TBL] [Abstract][Full Text] [Related]
17. Progress in the evaluation of CDK inhibitors as anti-tumor agents.
McInnes C
Drug Discov Today; 2008 Oct; 13(19-20):875-81. PubMed ID: 18639646
[TBL] [Abstract][Full Text] [Related]
18. [Prevention of chemotherapy-induced alopecia by cyclin-dependant kinase inhibitors].
Meijer L; Knockaert M; Damiens E
Bull Cancer; 2001 Apr; 88(4):347-50. PubMed ID: 11371368
[TBL] [Abstract][Full Text] [Related]
19. [A novel small molecule cyclin-dependent kinase inhibitor flavopiridol in cancer therapy].
Song Y; Shen J
Zhonghua Yi Xue Za Zhi; 2005 Mar; 85(12):862-4. PubMed ID: 15949412
[No Abstract] [Full Text] [Related]
20. [Research on cyclin-dependent kinase inhibitors: state of the art and perspective].
Zuo MX; Chen XG
Zhonghua Zhong Liu Za Zhi; 2007 May; 29(5):321-4. PubMed ID: 17892123
[No Abstract] [Full Text] [Related]
[Next] [New Search]